A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

Completed · Phase 2

Conditions studied: Renal Transplantation, Graft Rejection

In brief

This study involves the use of a drug called Thymoglobulin, which is approved in the US to treat kidney transplant rejection and in Canada to treat and to prevent kidney transplant rejection. This study will evaluate the effect of Thymoglobulin and reduced doses of steroids to prevent renal transplant rejection and will provide a basis for future evaluations of Thymoglobulin as an immunosuppressive agent to help prevent renal transplant rejection. Subjects meeting all inclusion and exclusion criteria are eligible to participate in this study. In addition to standard treatment, study participants will receive either Thymoglobulin with rapid discontinuation of steroids or steroids per hospital standards for at least the first 90 days after transplant. The treatment assignment is random and is not chosen by the subject or their physician. Subjects will be monitored during treatment with Thymoglobulin and during the transplant hospitalization. Additional subject monitoring occurs at Months 1, 3, 6 and 12 following the transplant. Approximately 150 study subjects from 15-20 transplant centers in the United States will be enrolled.

Key facts

Study ID: NCT00089947
Run by: Genzyme, a Sanofi Company
People needed: 150
Starts: 2003-06-01
Expected to finish: 2005-12-01
Last updated by the study team: 2015-03-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Adult living donor renal transplant recipient
Age greater than or equal to 18
If female and of childbearing potential: a) must not be lactating; b) must have a negative serum B-human chorionic gonadotropin (HCG) test within 24 hours prior to Study Day 0 (Day of Transplant) and; c) must agree to practice an acceptable and reliable form of contraception during the study; and
Signed informed consent

You may not qualify if…

Human Leukocyte Antibody (HLA) identical matched living donor transplant recipient
> 2 previous transplants
Current panel reactive antibody (PRA) > 20%
History of a positive cross-match with the donor
Active donor or recipient serology positive for human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis C virus (HCV)
Loss of first kidney transplant in < 1 year
History of noncompliance in clinical trial(s)
History of chronic CS or immunosuppressive use except for inhaled CS to treat asthma
Use of any investigational products during the 90 days prior to screening
Requirement for multiple organ transplant
Patient without a functioning urinary bladder prior to transplant (e.g. patients with self catheterization will be excluded)
Known contraindication to administration of rabbit antithymocyte globulin
Currently abusing drugs or alcohol
In the opinion of the investigator, at high risk for poor compliance
In the opinion of the investigator, has a significant medical or psychosocial problem or unstable disease state that warrants exclusion from the study. Examples of significant problems include, but are not limited to morbid obesity and severe cardiac disease.

Where it is running

University of Arkansas for Medical Science — Little Rock, Arkansas, United States
Keck USC School of Medicine — Los Angeles, California, United States
University of California, Los Angeles Medical Center — Los Angeles, California, United States
University of California, San Diego Medical Center — San Diego, California, United States
California Pacific Medical Center — San Francisco, California, United States
University of California, San Francisco — San Francisco, California, United States
University of Colorado Health Sciences Center — Denver, Colorado, United States
Emory University — Atlanta, Georgia, United States
Indiana University — Indianapolis, Indiana, United States
Oschner Medical Center — New Orleans, Louisiana, United States
Johns Hopkins University Hospital — Baltimore, Maryland, United States
Saint Barnabas Medical Center — Livingston, New Jersey, United States
Mount Sinai School of Medicine — New York, New York, United States
Duke University Medical Center — Durham, North Carolina, United States
Christ Hospital — Cincinnati, Ohio, United States
University of Cincinnati Medical Center — Cincinnati, Ohio, United States
Texas Transplant Institute — San Antonio, Texas, United States
Medical College of Virginia — Richmond, Virginia, United States
Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.